Genetic Determinants of Toxicity
Genetic variation across patients can shape immune reactivity, inflammation, drug metabolism, and recovery patterns. Our work investigates how germline genetics contribute to the risk of treatment-related adverse events, with particular focus on immune-related toxicities associated with immune checkpoint inhibitors (ICIs). We study genetic drivers of both acute and chronic toxicities, including patterns that may predispose patients to persistent endocrine, rheumatologic, dermatologic, pulmonary, or neurologic effects.
We integrate candidate immune pathways with broad genomic discovery approaches to identify genetic variants and immune signatures associated with toxicity risk. This includes investigating immunogenetic features such as HLA variation, autoimmunity-related markers, SNPs and inherited susceptibility to immune dysregulation. Our long-term goal is to enable pre-treatment risk stratification—supporting safer therapy selection, improved monitoring, and earlier intervention for patients at elevated risk.